C4 Therapeutics

Q2 FY2026 EarningsQ2 FY26 results outperformed consensus expectations across all key financial metrics, primarily driven by higher-than-expected collaboration revenue from the new Roche agreement and disciplined cost management. Revenue of $6.6M beat the $4.0M consensus by 66%, while the GAAP EPS loss of $0.18 was narrower than the expected $0.23 loss. The company reinforced its strong liquidity position with $300.4M in cash, extending its operational runway through year-end 2028.